Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung functionAUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") ...

IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

Leerink Partners 2026 Global Healthcare Conference March 8 – 11, 2026, Miami, Florida Fireside Chat: March 11, 8:40 a.m. ET Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, ...

Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopathic pulmonary fibrosis (IPF). United’s Teton-2 ...

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

The American College of Chest Physicians (CHEST), the PF Warriors, the Rare Disease Diversity Coalition (RDDC)-a program at the Black Woman's Health Imperative-and the National Association of ...

Please provide your email address to receive an email when new articles are posted on . Disease progression occurred in more patients receiving placebo vs. an oral lysophosphatidic acid receptor 1 ...

Project Leader: Steven Duncan, M.D. Idiopathic pulmonary fibrosis (IPF) is a morbid fibroproliferative lung disease of older adults that causes progressive dyspnea and hypoxemia. Current treatments ...